Dr. Benjamin P. Davis, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Medical school
- University of Iowa, Rj & L Carver College of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 114
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: University of Iowa, Rj & L Carver College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
IA license 42866 · OH license 35.121205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Iowa Hospital & Clinics Iowa City, IA
Medical groups
- State University of Iowa (1,897 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 114
- Services billed
- 198
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 108 | 82 |
| New patient office or other outpatient visit, 45-59 minutes | 29 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Azelastine Hcl Other prescribers in Iowa City, IA | 37 |
| Montelukast Sodium Other prescribers in Iowa City, IA | 29 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Iowa City, IA | 22 |
| Dupixent Syringe (dupilumab) Other prescribers in Iowa City, IA | 20 |
| Azithromycin Other prescribers in Iowa City, IA | 19 |
| Fluticasone Propionate Other prescribers in Iowa City, IA | 15 |
| Famotidine Other prescribers in Iowa City, IA | 12 |
| Gamunex-C (immune globul g/gly/iga avg 46) | 12 |
| Arnuity Ellipta (fluticasone furoate) Other prescribers in Iowa City, IA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $25.00 in total to this clinician.
| Ionis Pharmaceuticals, Inc. | $25.00 |
|---|
| Education | $25.00 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ionis Pharmaceuticals, Inc. Oct 1, 2025 | Education in-kind | $25.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $7,709 in research payments for these studies, mostly to the institutions running them.
- Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
Regeneron Pharmaceuticals, Inc. · Completed · NCT04394351
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.